[1] WHO. Summary of the global HIV epidemic, 2022. Geneve: World Health Organization. https://www.who.int/images/default-source/departments/hiv/summary-of-the-global-hiv-epidemic-2021.png?sfvrsn=73ac5b6a_9. [2022-05-13
[2] Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet, 2004; 364, 1236−43. doi:  10.1016/S0140-6736(04)17140-7
[3] Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med, 2008; 359, 2233−44. doi:  10.1056/NEJMoa0800971
[4] Mulisa D, Tesfa M, Kassa GM, et al. Determinants of first line antiretroviral therapy treatment failure among adult patients on ART at central Ethiopia: un-matched case control study. BMC Infect Dis, 2019; 19, 1024. doi:  10.1186/s12879-019-4651-6
[5] Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med, 2010; 363, 1510−20. doi:  10.1056/NEJMoa1000931
[6] Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med, 2012; 366, 2380−9. doi:  10.1056/NEJMoa1113249
[7] Barlow-Mosha L, Angelidou K, Lindsey J, et al. Nevirapine- versus Lopinavir/ritonavir-based antiretroviral therapy in HIV-infected infants and young children: long-term follow-up of the IMPAACT P1060 randomized trial. Clin Infect Dis, 2016; 63, 1113−21. doi:  10.1093/cid/ciw488
[8] Angdembe MR, Rai A, Bam K, et al. Predictors of mortality in adult people living with HIV on antiretroviral therapy in Nepal: A retrospective cohort study, 2004-2013. PLoS One, 2019; 14, e0215776. doi:  10.1371/journal.pone.0215776
[9] Kibuuka H, Musingye E, Mwesigwa B, et al. Predictors of all-cause mortality among people with human immunodeficiency virus (HIV) in a prospective cohort study in East Africa and Nigeria. Clin Infect Dis, 2022; 75, 657−64. doi:  10.1093/cid/ciab995
[10] Ebissa G, Deyessa N, Biadgilign S. Predictors of early mortality in a cohort of HIV-infected children receiving high active antiretroviral treatment in public hospitals in Ethiopia. AIDS Care, 2015; 27, 723−30. doi:  10.1080/09540121.2014.997180